Drug Trial Radar · NCT00333840
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Last checked: Nov 19, 2026Latest source record: Oct 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,106
Actual
Start
Jun 2000
Primary completion
Mar 2012
Study completion Mar 2012
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 6, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate and compare the side effects and anti-leukemic benefits of imatinib with those of interferon and Ara-C for patients who have chronic myeloid leukemia (CML) in the chronic phase. Patients in this study will be randomized (1:1) to receive either interferon plus Ara-C or imatinib as initial treatment.
Conditions
- Chronic Myelogenous Leukemia
Interventions
imatinib mesilateDrug
imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.
interferon-alpha (INF-a)Drug
interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day.
cytarabine (ARA-C)Drug
cytarabine 20 mg/m\^2/day (max 40 mg) SC for 10 days every month.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Kaplan-Meier Estimates of Overall Survival (All Randomized Participants)Time frame: 12,24,36,48,60,72,84,96,108,120,132 and 144 months
Locations
163 sites in 16 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Montgomery, Alabama
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Berkeley, California
Novartis Investigative Site
Campbell, California
Novartis Investigative Site
Duarte, California
Novartis Investigative Site
La Jolla, California
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
Atlanta, Georgia
Novartis Investigative Site
Honolulu, Hawaii
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Decatur, Illinois
Novartis Investigative Site
Beech Grove, Indiana
Novartis Investigative Site
Witchita, Kansas
Novartis Investigative Site
Louisville, Kentucky
Novartis Investigative Site
New Orleans, Louisiana
Novartis Investigative Site
Baltimore, Maryland
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Worcester, Massachusetts
Novartis Investigative Site
Ann Arbor, Michigan
Novartis Investigative Site
Detroit, Michigan
Novartis Investigative Site
East Lansing, Michigan
Novartis Investigative Site
Minneapolis, Minnesota
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Billings, Montana
Novartis Investigative Site
Omaha, Nebraska
Novartis Investigative Site
Hackensack, New Jersey
Novartis Investigative Site
Albuquerque, New Mexico
Novartis Investigative Site
Albuquerque, New Mexico
Novartis Investigative Site
Farmington, New Mexico
Novartis Investigative Site
Buffalo, New York
Novartis Investigative Site
New York, New York
Novartis Investigative Site
New York, New York
Novartis Investigative Site
New York, New York
Novartis Investigative Site
Syracuse, New York
Novartis Investigative Site
Chapel Hill, North Carolina
Showing 40 of 163 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.